

## University of Groningen

### AMR - An R Package for Working with Antimicrobial Resistance Data

Berends, Matthijs S.; Luz, Christian F.; Friedrich, Alexander W.; Sinha, Bhanu N.M.; Albers, Casper J.; Glasner, Corinna

DOI:  
[10.1101/810622](https://doi.org/10.1101/810622)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Early version, also known as pre-print

*Publication date:*  
2019

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Berends, M. S., Luz, C. F., Friedrich, A. W., Sinha, B. N. M., Albers, C. J., & Glasner, C. (2019). *AMR - An R Package for Working with Antimicrobial Resistance Data*. (bioRxiv). <https://doi.org/10.1101/810622>

#### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

#### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# AMR - An R Package for Working with Antimicrobial Resistance Data

Matthijs S. Berends  
University of Groningen

Christian F. Luz  
University of Groningen

Alexander W. Friedrich  
University of Groningen

Bhanu N.M. Sinha  
University of Groningen

Casper J. Albers  
University of Groningen

Corinna Glasner  
University of Groningen

---

## Abstract

Antimicrobial resistance is an increasing threat to global health. Evidence for this trend is generated in microbiological laboratories through testing microorganisms for resistance against antimicrobial agents. International standards and guidelines are in place for this process as well as for reporting data on (inter-)national levels. However, there is a gap in the availability of standardized and reproducible tools for working with laboratory data to produce the required reports. It is known that extensive efforts in data cleaning and validation are required when working with data from laboratory information systems. Furthermore, the global spread and relevance of antimicrobial resistance demands to incorporate international reference data in the analysis process.

In this paper, we introduce the **AMR** package for R that aims at closing this gap by providing tools to simplify antimicrobial resistance data cleaning and analysis, while incorporating international guidelines and scientifically reliable reference data. The **AMR** package enables standardized and reproducible antimicrobial resistance analyses, including the application of evidence-based rules, determination of first isolates, translation of various codes for microorganisms and antimicrobial agents, determination of (multi-drug) resistant microorganisms, and calculation of antimicrobial resistance, prevalence and future trends. The **AMR** package works independently of any laboratory information system and provides several functions to integrate into international workflows (e.g. WHONET software provided by the World Health Organization).

*Keywords:* Antimicrobial resistance, data analysis, R, software, epidemiology.

---

## 1. Introduction

Antimicrobial resistance is a global health problem and of great concern for human medicine, veterinary medicine, and the environment alike. It is associated with significant burdens to both patients and health care systems. Current estimates show the immense dimensions we are already facing, such as claiming at least 50,000 lives due to antimicrobial resistance each year across Europe and the US alone (O’Neil 2014). Although estimates for the burden

through antimicrobial resistance and their predictions are disputed (de Kraker *et al.* 2016) the rising trend is undeniable (CDC 2019), thus calling for worldwide efforts on tackling this problem.

Surveillance programs and reliable data are key for controlling and streamlining these efforts. Surveillance data of antimicrobial resistance at higher levels (national or international) usually comprise aggregated numbers. The basis of this information is generated and stored at local microbiological laboratories where isolated microorganisms are tested for their susceptibility to a whole range of antimicrobial agents. The efficacy of these agents against microorganisms is nowadays interpreted as follows (EUCAST 2019):

- R (“resistant”) - there is a high likelihood of therapeutic *failure*;
- S (“susceptible, standard dosing regimen”) - there is a high likelihood of therapeutic *success* using a standard dosing regimen of an antimicrobial agent;
- I (“susceptible, increased exposure”) - there is a high likelihood of therapeutic *success*, but only when exposure to an antimicrobial agent is increased by adjusting the dosing regimen or its concentration at the site of infection.

Generally, antimicrobial resistance is defined as the proportion of R (%R), while antimicrobial susceptibility is defined as the proportion of S and I (%SI). Today, the two major guideline institutes to define the international standards on antimicrobial resistance are the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Leclercq *et al.* 2013) and the Clinical and Laboratory Standards Institute (CLSI) (Clinical and Laboratory Standards Institute 2014). The guidelines from these two institutes are adopted by 94% of all countries reporting antimicrobial resistance to the WHO (World Health Organization 2018a).

Although these standardized guidelines are in place on the laboratory level for the data generation process, stored data in laboratory information systems are often not yet suitable for data analysis. Laboratory information systems are often designed to fit billing purposes rather than epidemiological data analysis. Furthermore, (inter-)national surveillance is hindered by inadequate standardization of epidemiological definitions, different types of samples and data collection, settings included, microbiological testing methods (including susceptibility testing), and data sharing policies (Tacconelli *et al.* 2018). The necessity of accurate data analysis in the field of antimicrobial resistance has just recently been further underlined (Limmathurotsakul *et al.* 2019). Antimicrobial resistance analyses require a thorough understanding of microbiological tests and their results, the biological taxonomy of microorganisms, the clinical and epidemiological relevance of the results, their pharmaceutical implications, and (inter-)national standards and guidelines for working with and reporting antimicrobial resistance.

Here, we describe the **AMR** package for R, which has been developed to standardize clean and reproducible antimicrobial resistance data analyses using international standardized recommendations (Leclercq *et al.* 2013; Clinical and Laboratory Standards Institute 2014) while incorporating scientifically reliable reference data about valid laboratory outcome, antimicrobial agents, and the complete biological taxonomy of microorganisms. The **AMR** package provides solutions and support for these aspects while being independent of underlying laboratory information systems, thereby democratizing the analysis process. Developed in R and available on the Comprehensive R Archive Network (CRAN) since February 22<sup>nd</sup> 2018

(Berends *et al.* 2019), the **AMR** package enables reproducible workflows as described in other fields, such as environmental science (Lowndes *et al.* 2017). The **AMR** package provides a new technical instrument to aid in curbing the global threat of antimicrobial resistance. Furthermore, local and regional data in the laboratories can now become relevant in any setting for public health. To the best of our knowledge, no other R package with this purpose is available on CRAN or Bioconductor.

The following sections describe the functionality of the **AMR** package according to its core functionalities for transforming, enhancing, and analyzing antimicrobial resistance data using scientifically reliable reference data.

## 2. Antimicrobial resistance data

Microbiological tests can be performed on different specimens, such as blood or urine samples or nasal swabs. After arrival at the microbiological laboratory, the specimens are traditionally cultured on specific media, such as blood agar. If a microorganism can be isolated from these media, it is tested against several antimicrobial agents. Based on the minimal inhibitory concentration (MIC) of the respective drug and interpretation guidelines, such as guidelines by EUCAST (Leclercq *et al.* 2013) and CLSI (Clinical and Laboratory Standards Institute 2014), test results are reported as “resistant” (R), “susceptible” (S) or “susceptible, increased exposure” (I). A typical data structure is illustrated in Table 1 (Leclercq *et al.* 2013).

Table 1: Example of an antimicrobial resistance report.

patient	date	test_no	specimen	mo	PEN	AMC	CIP
000001	2019-03-08	100	blood	esccol	R	I	S
000001	2019-03-09	101	blood	esccol	R	I	S
000002	2019-03-08	102	blood	staur	R	S	-
000003	2019-03-08	103	urine	pseae	R	R	R

Abbreviations: R = resistant, S = susceptible, I = susceptible, increased exposure, mo = microorganism, PEN = penicillin, AMC = amoxicillin/clavulanic acid, CIP = ciprofloxacin

For the first two rows, the information should be read as: *Escherichia coli* (mo code = `esccol`) was isolated from blood of patient 000001 and was found to be resistant to penicillin, and susceptible to amoxicillin/clavulanic acid and ciprofloxacin. However, often (especially when merging sources) data is reported in ambiguous formats as exemplified in Table 2. It is crucial that source data can be analyzed in a reliable way, especially when the outcome will be used to evaluate patient treatment options. This requires reproducible and field-specific, specialized data cleaning and transforming.

The **AMR** package aims at providing a standardized and automated way of cleaning, transforming, and enhancing these typical data structures (Table 1 and 2), independent of the underlying data source. Processed data would be similar to Table 3 that highlights several package functionalities in the sections below.

## 3. Antimicrobial resistance data transformation

The **AMR** package follows the rationale of **tidyverse** packages as authored by Wickham *et al.*

Table 2: Antimicrobial resistance report example - ambiguous formats.

patient	date	test_no	specimen	mo	PEN	AMC	CIP
1	2019-03-08	100	blood	esccol	R	I	S
1	2019-03-09	101	blood	esccol	R	I	S
2	2019-03-08	102	blood	StaAur	>8 (R)*	<0.01 (S)*	.
00003	2019-03-08	103	urine	P. aeru.	R	S**	S

\* Mixed reporting of minimal inhibitory concentration (MIC) and susceptibility interpretation of MIC value

\*\* False reporting; *Pseudomonas aeruginosa* (mo = P. aeru.) is intrinsically resistant to amoxicillin/clavulanic acid (AMC)

Abbreviations: R = resistant, S = susceptible, I = susceptible, increased exposure,

mo = microorganism, PEN = penicillin, AMC = amoxicillin/clavulanic acid, CIP = ciprofloxacin

Table 3: Enhanced antimicrobial resistance report example.

patient	date	test_no	specimen	mo <sup>a</sup>	PEN <sup>b</sup>	AMC <sup>b</sup>	CIP <sup>b</sup>	first_isolate <sup>c</sup>	name <sup>d</sup>	gram_stain <sup>e</sup>
000001	2019-03-08	100	blood	B_ESCHR_COL	R	I	S	TRUE	Escherichia coli	Gram-negative
000001	2019-03-09	101	blood	B_ESCHR_COL	R	I	S	FALSE	Escherichia coli	Gram-negative
000002	2019-03-08	102	blood	B_STPHY_AUR	R	S	NA	TRUE	Staphylococcus aureus	Gram-positive
000003	2019-03-08	103	urine	B_PSDMN_AER	R	R	S	TRUE	Pseudomonas aeruginosa	Gram-negative

a) `as.mo()` function

b) `eucastr_rules()` function applied

c) `first_isolate()` function

d) `mo_name()` function

e) `mo_gramstain()` function

Abbreviations: R = resistant, S = susceptible, I = susceptible, increased exposure,

mo = microorganism, PEN = penicillin, AMC = amoxicillin/clavulanic acid, CIP = ciprofloxacin

(2019a). Most functions take a 'data.frame' or 'tibble' as input, support piping (%>) operations, can work with quasi-quotations, and can be integrated into **dplyr** workflows, such as `mutate()` to create new variables and `group_by()` to group by variables.

### 3.1. Working with taxonomically valid microorganism names

Coercing is a computational process of forcing output based on an input. For microorganism names, coercing user input to taxonomically valid microorganism names is crucial to ensure correct interpretation and to enable grouping based on taxonomic properties. To this end, the **AMR** package includes all microbial entries from The Catalogue of Life (<http://www.catalogueoflife.org>), the most comprehensive and authoritative global index of species currently available (Roskov *et al.* 2019). It holds essential information on the names, relationships, and distributions of more than 1.9 million species. The integration of it into the **AMR** package is described in Section 8.

The `as.mo()` function makes use of this underlying data to transform a vector of characters to a new class 'mo' of taxonomically valid microorganism name. The resulting values are microbial IDs, which are human-readable for the trained eye and contain information about the taxonomic kingdom, genus, species, and subspecies (Figure 1).

The `as.mo()` function uses several coercion rules for fast and logical results. It assesses the input matching criteria in the following order:

1. Human pathogenic prevalence: the function starts with more prevalent microorganisms, followed by less prevalent ones;




Figure 1: The structure of a typical microbial ID as used in the **AMR** package. An ID consists of two to four elements, separated by an underscore. The first element is the abbreviation of the taxonomic kingdom. The remaining elements consist of abbreviations of the lowest taxonomic levels of every microorganism: genus, species (if available) and subspecies (if available). Abbreviations used for the microbial IDs of microorganism names were created using the base R function `abbreviate()`.

2. Taxonomic kingdom: the function starts with determining Bacteria, then Fungi, then Protozoa, then others;
3. Breakdown of input values to identify possible matches.

This will lead to the effect that e.g. "E. coli" (a highly prevalent microorganism found in humans) will return the microbial ID of *Escherichia coli* and not *Entamoeba coli* (a less prevalent microorganism in humans), although the latter would alphabetically come first. In addition, the `as.mo()` function can differentiate four levels of uncertainty to guess valid results:

- Uncertainty level 0: no additional rules are applied;
- Uncertainty level 1: allow previously accepted (but now invalid) taxonomic names and minor spelling errors;
- Uncertainty level 2 (default): allow all of level 1, strip values between brackets, inverse the words of the input, strip off text elements from the end keeping at least two elements;
- Uncertainty level 3: allow all of level 1 and 2, strip off text elements from the end, allow any part of a taxonomic name.

These rules consider the prevalence of microorganisms in humans. The grouping into three prevalence groups is based on experience from several microbiological laboratories in the Netherlands in conjunction with international reports on pathogen prevalence (de Greeff *et al.* 2019; European Centre for Disease Prevention and Control 2010; World Health Organization 2018a). Group 1 (most prevalent microorganisms) consists of all microorganisms where the taxonomic class is Gammaproteobacteria or where the taxonomic genus is *Enterococcus*, *Staphylococcus* or *Streptococcus*. This group consequently contains all common Gram-negative



bacteria, such as *Pseudomonas* and *Legionella* and all species within the order Enterobacterales. Group 2 consists of all microorganisms where the taxonomic phylum is Proteobacteria, Firmicutes, Actinobacteria or Sarcomastigophora, or where the taxonomic genus is *Abisidia*, *Acremonium*, *Actinotignum*, *Alternaria*, *Anaerosalibacter*, *Apophysomyces*, *Arachnia*, *Aspergillus*, *Aureobacterium*, *Aureobasidium*, *Bacteroides*, *Basidiobolus*, *Beauveria*, *Blastocystis*, *Branhamella*, *Calymmatobacterium*, *Candida*, *Capnocytophaga*, *Catabacter*, *Chaetomium*, *Chryseobacterium*, *Chryseomonas*, *Chrysonilia*, *Cladophialophora*, *Cladosporium*, *Conidiobolus*, *Cryptococcus*, *Curvularia*, *Exophiala*, *Exserohilum*, *Flavobacterium*, *Fonsecaea*, *Fusarium*, *Fusobacterium*, *Hendersonula*, *Hypomyces*, *Koserella*, *Lelliottia*, *Leptosphaeria*, *Leptotrichia*, *Malassezia*, *Malbranchea*, *Mortierella*, *Mucor*, *Mycocentrospora*, *Mycoplasma*, *Nectria*, *Ochroconis*, *Oidiodendron*, *Phoma*, *Piedraia*, *Pithomyces*, *Pityrosporum*, *Prevotella*, *Pseudallescheria*, *Rhizomucor*, *Rhizopus*, *Rhodotorula*, *Scolecobasidium*, *Scopulariopsis*, *Scytalidium*, *Sporobolomyces*, *Stachybotrys*, *Stomatococcus*, *Treponema*, *Trichoderma*, *Trichophyton*, *Trichosporon*, *Tritirachium* or *Ureaplasma*. Group 3 consists of all other microorganisms.

To support organization specific codes, users can specify a custom reference 'data.frame' for looking up codes, that can be set with `as.mo(..., reference_df = ...)`. This process can be automated by users with the `set_mo_source()` function.

### *Properties of microorganisms*

The package contains functions to return a specific (taxonomic) property of a microorganism from the `microorganisms` data set (see Section 8). Using functions that start with `mo_*` can be used to retrieve the most recently defined taxonomic properties of any microorganism quickly and conveniently. These functions rely on `as.mo()` internally: `mo_name()`, `mo_fullname()`, `mo_shortname()`, `mo_subspecies()`, `mo_species()`, `mo_genus()`, `mo_family()`, `mo_order()`, `mo_class()`, `mo_phylum()`, `mo_kingdom()`, `mo_type()`, `mo_gramstain()`, `mo_ref()`, `mo_authors()`, `mo_year()`, `mo_rank()`, `mo_taxonomy()`, `mo_synonyms()`, `mo_info()` and `mo_url()`. Determination of the Gram stain, with `mo_gramstain()`, is based on the taxonomic subkingdom and phylum. According to Cavalier-Smith (2002), who defined the subkingdoms Negibacteria and Posibacteria, only the following phyla are Posibacteria: Actinobacteria, Chloroflexi, Firmicutes and Tenericutes. Bacteria from these phyla are considered Gram-positive - all other bacteria are considered Gram-negative. Gram stains are only relevant for species within the kingdom of Bacteria. For species outside this kingdom, `mo_gramstain()` will return NA.

## 3.2. Working with antimicrobial names or codes

The **AMR** package includes the `antibiotics` data set, which comprises common laboratory information system codes, official names, ATC (Anatomical Therapeutic Chemical) codes, defined daily doses (DDD) and more than 5,000 trade names of 452 antimicrobial agents (see Section 8). The ATC code system and the reference list for DDDs have been developed and made available by the World Health Organization Collaborating Centre for Drug Statistics Methodology (WHOC) to standardize pharmaceutical classifications (WHO Collaborating Centre for Drug Statistics Methodology 2018). All agents in the `antibiotics` data set have a unique antimicrobial ID, which is based on abbreviations used by the European Antimicrobial Resistance Surveillance Network (EARS-Net), the largest publicly funded system for antimicrobial resistance surveillance in Europe (European Centre for Disease Prevention and

[Control 2018](#)). Furthermore, the **AMR** package includes the `antivirals` data set containing antiviral agents, which is also described in Section 8.

### *Properties of antimicrobial agents*

It is a common task in microbiological data analyses (and other clinical or epidemiological fields) to work with different antimicrobial agents. The **AMR** package provides several functions to translate inputs such as ATC codes, abbreviations, or names in any direction. Using `as.ab()`, any input will be transformed to an antimicrobial ID of class `'ab'`. Helper functions are available to get specific properties of antimicrobial IDs, such as `ab_name()` getting the official name, `ab_atc()` the ATC code, or `ab_cid()` the CID (Compound ID) used by PubChem ([Kim et al. 2019](#)). Trade names can be also used as input. For example, the input values "Amoxil", "dispermox", "amox" and "J01CA04" all return the ID of amoxicillin (AMX):

```
R> as.ab("Amoxicillin")

Class 'ab'
[1] AMX

R> as.ab(c("Amoxil", "dispermox", "amox", "J01CA04"))

Class 'ab'
[1] AMX AMX AMX AMX

R> ab_name("Amoxil")

[1] "Amoxicillin"

R> ab_atc("amox")

[1] "J01CA04"

R> ab_name("J01CA04")

[1] "Amoxicillin"
```

### *Filtering data based on classes of antimicrobial agents*

The application of the ATC classification system also enables grouping of antimicrobial agents for data analyses. Data sets with microbial isolates can be filtered on isolates with specific results for tested antimicrobial agents in a specific antimicrobial class. For example, using `filter_cephalosporins(result = "R")` returns data of all isolates with tested resistance to any of the available antimicrobial agents in the group of cephalosporins.

## 3.3. Other new S3 classes

S3 classes are object oriented (OO) systems available in R. The classes `'mo'` and `'ab'` that are discussed above are S3 classes, which means that they allow different types of output based on



the user input. Three other new S3 classes that come with this package are 'mic', 'disk', and 'rsi'. The 'mic' class can be used to clean MIC (minimal inhibitory concentration) values. MIC values are susceptibility test results measured by microbiological laboratory equipment to determine at which minimum antimicrobial drug concentration 99.9% of a microorganism is inhibited in growth. These concentrations are often capped at a minimum and maximum, such as  $\leq 0.02$  mg/ml and  $\geq 32$  mg/ml, respectively. The 'mic' class, an ordered 'factor', keeps these operators while still ordering all possible outcomes correctly, so that e.g. " $\leq 0.02$ " will be considered lower than "0.04".

Another susceptibility testing method is the use of drug diffusion disks, which are small tablets containing a specified concentration of antimicrobial agents. These disks are applied onto a solid growth medium, or a specific agar plate. After 24 hours of incubation, the diameter of the growth inhibition around a disk can be measured in millimeters with a ruler. The 'disk' class can be used to clean these kinds of measurements, since they should always be valid numeric values between 8 and 50.

The higher the MIC or the smaller the growth inhibition diameter, the more active substance of an antimicrobial drug is needed to inhibit cell growth (i.e. the higher the antimicrobial resistance of the tested isolate against the tested antimicrobial agent). At high MICs and small diameters, guidelines interpret the microorganism as “resistant” (R) to the tested antimicrobial agent. At low MICs and wide diameters, guidelines interpret the microorganism as “susceptible” (S) to the tested antimicrobial agent. In between, the microorganism is classified as “susceptible, increased exposure” (I). For these three interpretations the 'rsi' class has been developed. When using `as.rsi()` on MIC values (of class 'mic') or disk diffusion diameters (of class 'disk'), the values will be interpreted according to the guidelines from the CLSI or EUCAST (all guidelines between 2011 and 2019 are included in the **AMR** package) (Clinical and Laboratory Standards Institute 2019; The European Committee on Antimicrobial Susceptibility Testing 2019). Guidelines can be changed by setting the `guidelines` argument.

```
R> # Low MIC value
R> as.rsi(as.mic(2), "E. coli", "ampicillin", guideline = "EUCAST 2019")

Class 'rsi'
[1] S

R> # High MIC value
R> as.rsi(as.mic(32), "E. coli", "ampicillin", guideline = "EUCAST 2019")

Class 'rsi'
[1] R
```

When using the `as.rsi()` function on existing antimicrobial interpretations, it tries to coerce the input to the values “S”, “I”, or “R”. These values can in turn be used to calculate the proportion of antimicrobial resistance.

### 3.4. Interpretative rules by EUCAST

Next to supplying guidelines to interpret raw MIC values, the EUCAST has developed a set of expert rules to assist clinical microbiologists in the interpretation and reporting of antimi-

crobial susceptibility tests (Leclercq *et al.* 2013). The rules comprise assistance on intrinsic resistance, exceptional phenotypes, and interpretive rules. The **AMR** package covers intrinsic resistant and interpretive rules for data transformation and standardization purposes. The first prevents false susceptibility reporting by providing a list of organisms with known intrinsic resistance to specific antimicrobial agents (e.g. cephalosporin resistance of all enterococci). Interpretative rules apply inference from established resistance mechanisms (Winstanley and Courvalin 2011; Courvalin 1992, 1996; Livermore *et al.* 2001). Both groups of rules are based on classic IF THEN statements (e.g. IF *Enterococcus spp.* resistant to ampicillin THEN report as resistant to carbapenems). Some rules provide assistance for further actions when certain resistance has been detected, i.e. performing additional testing of the isolated microorganism. The **AMR** package function `eucast_rules()` can apply all EUCAST rules that do not rely on additional clinical information, such as additional information on patients' diagnoses. Applied changes can be reviewed by setting the argument `eucast_rules(..., verbose = TRUE)`. Table 2 and 3 highlight the transformation for the reporting of AMX = S in patient\_id = 000003 to the correct report according to EUCAST rules of AMX = R.

### 3.5. Working with defined daily doses (DDD)

DDDs are essential when standardizing antimicrobial consumption analysis for inter-institutional or international comparison. The official DDDs are published by the WHOCC and subject to regular updates (WHO Collaborating Center for Drug Statistics Methodology 2019). Other metrics exist such as the recommended daily dose (RDD) or the prescribed daily dose (PDD). However, DDDs are the only metric that is independent of a patient's disease and therapeutic choices and thus suitable for the **AMR** package.

Functions from the `atc_online_*()` family take any text as input that can be coerced with `as.ab()` (i.e. to class 'ab'). Next, the functions access the WHOCC online registry (WHO Collaborating Center for Drug Statistics Methodology 2019) (internet connection required) and download the property defined in the arguments (e.g. `administration = "O"` or `administration = "P"` for oral or parenteral administration and `property = "ddd"` or `property = "groups"` to get DDD or the group of the selected antimicrobial defined by its ATC code).

```
R> atc_online_ddd("amoxicillin", administration = "O")
```

```
[1] 1.5
```

```
R> atc_online_groups("amoxicillin")
```

```
[1] "ANTIINFECTIVES FOR SYSTEMIC USE"
[2] "ANTIBACTERIALS FOR SYSTEMIC USE"
[3] "BETA-LACTAM ANTIBACTERIALS, PENICILLINS"
[4] "Penicillins with extended spectrum"
```

## 4. Enhancing antimicrobial resistance data

#### 4.1. Determining first isolates

Determining antimicrobial resistance or susceptibility can be done for a single drug (monotherapy) or multiple drugs (combination therapy). The calculation of antimicrobial resistance statistics is dependent on two prerequisites: the data should only comprise the first isolates and a minimum required number of 30 isolates should be met for every stratum in further analysis ([Clinical and Laboratory Standards Institute 2014](#)).

An isolate is a microorganism strain cultivated on specified growth media in a laboratory, so its phenotype can be determined. First isolates are isolates of any species found first in a patient per episode, regardless of the body site or the type of specimen (such as blood or urine) ([Clinical and Laboratory Standards Institute 2014](#)). The selection on first isolates (using function `first_isolate()`) is important to prevent selection bias, as it would lead to overestimated or underestimated resistance to an antimicrobial agent. For example, if a patient is admitted with a multi-drug resistant microorganism and that microorganism is found in five different blood cultures the following week, it would overestimate resistance if all isolates were to be counted. The episode in days can be set with the argument `episode_days`, which defaults to 365 as suggested by the [Clinical and Laboratory Standards Institute \(2014\)](#) guideline.

#### 4.2. Determining multi-drug resistant organisms (MDRO)

Definitions of multi-drug resistant organisms (MDRO) are regulated by national and international expert groups and differ between nations. The **AMR** package provides the functionality to quickly identify MDROs in a data set using the `mdro()` function. Guidelines can be set with the argument `guideline`. At default, it applies the guideline as proposed by [Magiorakos \*et al.\* \(2012\)](#). Their work describes the definitions for bacteria being ‘MDR’ (multi-drug-resistant), ‘XDR’ (extensively drug-resistant) or ‘PDR’ (pandrug-resistant). These definitions are widely adopted ([Abat \*et al.\* 2018](#)) and known in the field of medical microbiology.

Other guidelines currently supported are the international EUCAST guideline (`guideline = "EUCAST"`, [European Committee on Antimicrobial Susceptibility Testing \(EUCAST\) \(2016\)](#)), the international WHO guideline on the management of drug-resistant tuberculosis (`guideline = "TB"`, [World Health Organization \(2014\)](#)), and the national guidelines of The Netherlands (`guideline = "NL"`, [Werkgroep Infectiepreventie \(WIP\) \(2011\)](#)), and Germany (`guideline = "DE"`, [Müller \*et al.\* \(2015\)](#)).

Some guidelines require a minimum availability of tested antimicrobial agents per isolate. This is needed to prevent false-negatives, since no reliable determination can be performed on only a few test results. This required minimum defaults to 50%, but can be set by the user with the `pct_minimum_classes`. Isolates that do not meet this requirement will be skipped for determination and will return NA (not applicable), with an informative warning printed to the console.

The rules are applied per row of the data. The `mdro()` function automatically identifies the variables containing the microorganism codes and antimicrobial agents based on the `guess_ab_col()` function. Following the guideline set by the user, it analyzes the specific antimicrobial resistance of a microorganism and flags that microorganism accordingly. The outcome is demonstrated in Table 4, where the first row is an MDRO according to the Dutch guidelines ([Werkgroep Infectiepreventie \(WIP\) 2011](#)).

Table 4: Example of a multi-drug resistant organism (MDRO) in a data set identified by applying Dutch guidelines.

mo	AMC	GEN	TOB	CIP	MFX	MDRO
B_ESCHR_COLI	S	R	R	R	R	Positive
B_ESCHR_COLI	R	S	R	R	S	Negative
B_ESCHR_COLI	S	S	S	R	S	Negative

Abbreviations: mo = microorganism, AMC = amoxicilline/clavulanic acid

GEN = gentamicin, TOB = tobramycin, CIP = ciprofloxacin, MFX = moxifloxacin,

MDRO = multi-drug resistant organism, B\_ESCHR\_COLI = microorganism code of *Escherichia coli*

The returned value is an ordered 'factor' with the levels 'Negative' < 'Positive, unconfirmed' < 'Positive'. For some guideline rules that require additional testing (e.g. molecular confirmation), the level 'Positive, unconfirmed' is returned.

### Multi-drug resistant tuberculosis

Tuberculosis is a major threat to global health caused by *Mycobacterium tuberculosis* (MTB) and is one of the top ten causes of death worldwide (World Health Organization 2018b). Exceptional antimicrobial resistance in MTB is therefore of special interest. To this end, the international WHO guideline for the classification of drug resistance in MTB (World Health Organization 2014) is included in the **AMR** package. The `mdr_tb()` function is a convenient wrapper around `mdro(..., guideline = "TB")`, which returns an other ordered 'factor' than other `mdro()` functions. The output will contain the 'factor' levels 'Negative' < 'Mono-resistant' < 'Poly-resistant' < 'Multi-drug-resistant' < 'Extensive drug-resistant', following the WHO guideline.

## 5. Analyzing antimicrobial resistance data

### 5.1. Calculation of antimicrobial resistance

The **AMR** package contains several functions for fast and simple resistance calculations of bacterial or fungal isolates. A minimum number of available isolates is needed for the reliability of the outcome. The CLSI guideline suggests a minimum of 30 available first isolates irrespective of the type of statistical analysis (Clinical and Laboratory Standards Institute 2014). Therefore, this number is used as the default setting for any function in the package that calculates antimicrobial resistance or susceptibility, which can be changed with the `minimum` argument in all applicable functions.

#### Counts

The **AMR** package relies on the concept of tidy data (Wickham 2014), although not strictly following its rules (one row per test rather than one row per observation). Function names to calculate the number of available isolates follow these general resistance interpretation standards with `count_S()`, `count_I()`, and `count_R()` respectively. Combinations of an-

timicrobial resistance interpretations can be counted with `count_SI()` and `count_IR()`. All these functions take a vector of interpretations of the class 'rsi' (as discussed above) or are internally transformed with `as.rsi()`. The returned value is the sum of the respective interpretation in the selected test column. All `count_*`() functions support quasi-quotation with pipes, grouped variables, and can be used with `dplyr::summarize()` (Wickham *et al.* 2019b).

### Proportions

Calculation of antimicrobial resistance is carried out by counting the number of first resistant isolates (interpretation of "R") and dividing it by the number of all first isolates, see Formula 1. This is implemented in the `proportion_R()` function. To calculate antimicrobial *susceptibility*, the number of susceptible first isolates (interpretation of "S" and "I") has to be counted and divided by the number of all first isolates, which is implemented in the `proportion_SI()` function. For convenience, the `resistance()` function is an alias of the `proportion_R()` function, and the `susceptibility()` function is an alias of the `proportion_SI()` function.

$$R_x = \frac{\sum x_z}{\sum x}, \quad (1)$$

where  $x$  is an antimicrobial agent,  $z$  is an antimicrobial interpretation ("S", "I", or "R") and  $R$  is the antimicrobial resistance.

The functions `proportion_R()`, `proportion_IR()`, `proportion_I()`, `proportion_SI()`, and `proportion_S()` follow the same logic as the `count_*`() functions and all return a vector of class 'double' with values between 0 and 1. The argument `minimum` defines the minimal allowed number of available (tested) isolates (default: `minimum = 30`). Any number below the set `minimum` will return NA with a warning.

For the proportion of empiric susceptibility for more than one antimicrobial agent, the total number of first isolates where at least one agent was tested as "S" or "I" must be divided by the number of first isolates tested where all agents were tested for any interpretation (see Formula 2 and Table 5).

$$R_{x,y} = \frac{\sum (x_z | y_z)}{\sum (x | y)}, \quad (2)$$

where  $x$  and  $y$  are antimicrobial agents,  $z$  is an antimicrobial interpretation: "S", "I", or "R" and  $R$  is the antimicrobial resistance.

Based on Formula 1, the overall resistance and susceptibility of antimicrobial agents like gentamicin (GEN) and amoxicillin (AMX) can be calculated using the following syntax. The `example_isolates` is an example data set included in the **AMR** package, see Section 8. The `n_rsi()` function is analogous to the `n()` function of the **dplyr** package. It counts the number of available isolates, but only includes observations with valid antimicrobial results (i.e. "S", "I", or "R").

```
R> library("dplyr")
R> example_isolates %>%
+   summarize(r_gen = proportion_R(GEN),
+             r_amx = proportion_R(AMX),
```

Table 5: Example calculation for determining empiric susceptibility (%SI) for more than one antimicrobial agent.

Antimicrobial agent		All isolates (only_all_tested = FALSE)		Only isolates tested for both agents (only_all_tested = TRUE)	
Agent A	Agent B	Include as numerator	Include as denominator	Include as numerator	Include as denominator
S or I or R	S or I	x	x	x	x
R	R		x		x
N/A	S or I	x	x		
N/A	R or N/A				

Abbreviations: R = resistant, S = susceptible, I = susceptible, increased exposure,  
N/A = not tested or missing

```

+           n_gen = n_rsi(GEN),
+           n_amx = n_rsi(AMX),
+           n_total = n())

      r_gen      r_amx n_gen n_amx n_total
1 0.2458221 0.5557364 1855 1229 2000

```

This output reads: the resistance to gentamicin of all isolates in the `example_isolates` data set is  $R_{GEN} = 24.6\%$ , based on 1855 out of 2000 available isolates. This means the susceptibility is  $1 - R_{GEN} = 75.4\%$ . The susceptibility to amoxicillin is  $1 - R_{AMX} = 55.6\%$  based on 1229 isolates.

To calculate the effect of combination therapy, i.e. treating patients with multiple agents at the same time, all `proportion_*` functions can handle multiple variables as arguments. For example, to calculate the empiric susceptibility of a combination therapy comprising gentamicin (GEN) and amoxicillin (AMX):

```

R> example_isolates %>%
+   summarize(si_gen_amx = proportion_SI(GEN, AMX),
+           n_gen_amx = n_rsi(GEN, AMX),
+           n_total = n())

      si_gen_amx n_gen_amx n_total
1 0.9328603      1919      2000

```

This leads to the conclusion that combining gentamicin with amoxicillin would cover 93.3% based on 1919 out of 2000 available isolates, which is 17.9% more than when treating with gentamicin alone ( $1 - R_{GEN} = 75.4\%$ ). With these functions, exact calculations can be done to evaluate the empiric success of inhibiting growth of microorganisms, by treating them with specified antimicrobial agents.

## 5.2. Prediction of antimicrobial resistance

The **AMR** package can handle several different regression models that can be used to predict antimicrobial resistance. The `resistance_predict()` function uses dates (argument

`col_date`) and a selected antimicrobial agent (argument `col_ab`) to estimate resistance rates of a specified number of upcoming years (default: `year_max = 10`). The user needs to specify the statistical model by setting the `model` argument. Valid options are generalized linear models with a binomial distribution or Poisson distribution, or a linear regression model. Furthermore, it is required to decide on the choice of interpreting isolates that are “susceptible, increased exposure” as “susceptible isolates” (default: `I_as_S = TRUE`). The minimum number of isolates per year defaults to 30 and can be set with the `minimum` argument.

The `resistance_predict()` function returns a ‘`data.frame`’ with an extra S3 class ‘`resistance_predict`’ and contains the following columns: `year`, `value`, `se_min` (the lower bound of the standard error with a minimum of 0), `se_max` (the upper bound of the standard error with a maximum of 1), `observations` (the total number of observations in the respective year, i.e. “S” + “I” + “R”), `observed` (the original observed resistant percentages), and `estimated` (the estimated resistant percentages calculated by the model). Furthermore, the model itself is available as an attribute: `attributes(x)$model`.

### 5.3. Plotting of antimicrobial resistance

The **AMR** package contains simple plotting functionalities to visualize antimicrobial resistance data. The `geom_rsi()` function for plotting data containing antimicrobial test results is extending the **ggplot2** package (Wickham 2016) with a new so-called ‘geom’, `geom_rsi()`. The output is fully editable and follows the common **ggplot2** code. Arguments include `position`, `fill`, and `facets` (relying on `ggplot2::facet_wrap()`). Moreover, the argument `translate_ab` uses `ab_name()` to translate abbreviations of antimicrobial agents into official names. Figure 2 demonstrates an example plotting function with a selection of antimicrobial agents commonly used to treat urinary tract infections.

```
R> library(ggplot2)
R> example_isolates %>%
+   select(AMX, NIT, FOS, TMP, CIP) %>%
+   ggplot() +
+   geom_rsi()
```






Figure 2: Selection of five variables from the `example_isolates` data set: **AMX** (amoxicillin), **NIT** (nitrofurantoin), **FOX** (fosfomycin), **TMP** (trimethoprim) and **CIP** (ciprofloxacin). These variables are passed onto `ggplot()` and the new 'geom' `geom_rsi()`, that automatically calculates antimicrobial resistance, translates the abbreviations of antimicrobial agents and plots the data.

In addition, the `ggplot_rsi()` function provides a wrapper around the `geom_rsi()` function, taking any kind of 'data.frame' as first input, so the function can be used after a pipe (`%>%`).

Prediction analyses can also be visualized with the **AMR** package. It extends the base R function `plot()`, but also contains a **ggplot2** wrapper with the function `ggplot_rsi_predict()` as shown in Figure 3.

```
R> example_isolates %>%
+   resistance_predict(col_ab = "TZP",
+                     model = "binomial") %>%
+   ggplot_rsi_predict()
```




Figure 3: Prediction of antimicrobial resistance to the TZP (piperacillin/tazobactam) variable from the `example_isolates` data set. A regression model with a binomial cumulative distribution function was chosen, assuming a period of very low resistance that cumulatively increases over time. The `ggplot_rsi_predict()` function calculates the antimicrobial resistance per year and plots the observations, followed by a prediction of the upcoming years. The grey ribbon denotes the standard error of the mean, calculated as  $S_{\bar{x}} = \frac{s}{\sqrt{n}}$ .

## 6. Reproducible example

A completely worked out example with fully annotated R code is available as supplementary material, with file name `complete_reproducible_example.R`.

## 7. Summary

This paper demonstrates the **AMR** package and its foremost use for working with antimicrobial resistance data. It can be used to clean, enhance, and analyze such data according to international recommendations and guidelines while incorporating scientifically reliable reference data on microbiological laboratory test results, antimicrobial agents, and the biological taxonomy of microorganisms. Consequently, it allows for reproducible analyses, regardless of the many possible ways in which raw and uncleaned data are stored in laboratory information systems.

While the burden of antimicrobial resistance is increasing worldwide, reliable data and data analyses are needed to better understand current and future developments. Open source approaches, such as the **AMR** package for R, have the potential to help democratizing the required tools in the field for researchers, clinicians, and policy makers alike. In organizations or countries with very limited resources, this free and open-source package could also

overcome a financial limitation that would otherwise hinder antimicrobial resistance analysis in these settings. Across settings, we believe the **AMR** package can be used to support clinical decision-making by providing improved insight into current local and regional resistance levels. Furthermore, data analysis approaches based on individual patient or microbiological data, which the **AMR** package enables, fosters empowerment of laboratory staff, infection control practitioners, and public health services.

## 8. Included data sets

- **microorganisms**

A 'data.frame' containing 69,447 (sub)species with 16 columns comprising their complete microbial taxonomy according to the Catalogue of Life (Roskov *et al.* 2019). Included microorganisms and their complete taxonomic tree of all included (sub)species from kingdom to subspecies with year of scientific publication and responsible author(s):

- All 57,776 (sub)species from the kingdoms of Archaea, Bacteria, Chromista and Protozoa;
- All 9,548 (sub)species from these orders of the kingdom of Fungi: Eurotiales, Onygenales, Pneumocystales, Saccharomycetales, Schizosaccharomycetales and Tremellales;
- All 2,122 (sub)species from 46 other relevant genera from the kingdom of Animalia (like *Strongyloides* and *Taenia*);
- All 24,253 previously accepted names of included (sub)species that have been taxonomically renamed.

The kingdom of Fungi is a very large taxon with almost 300,000 different (sub)species, of which most are not microbial (but rather macroscopic, such as mushrooms). Therefore, not all fungi fit the scope of the **AMR** package. By only including the aforementioned taxonomic orders, the most relevant fungi are covered (such as all species of *Aspergillus*, *Candida*, *Cryptococcus*, *Histoplasma*, *Pneumocystis*, *Saccharomyces* and *Trichophyton*).

- **antibiotics**

A 'data.frame' containing 452 antibiotic agents with 13 columns. All entries in this data set have three different identifiers: a human readable EARS-Net code (as used by ECDC (European Centre for Disease Prevention and Control 2010) and WHONET (WHO Collaborating Centre for Surveillance of Antimicrobial Resistance 2019) and primarily used by this package), an ATC code (as used by the WHO (WHO Collaborating Centre for Drug Statistics Methodology 2018)), and a CID code (Compound ID, as used by PubChem (Kim *et al.* 2019)). The data set contains more than 5,000 official brand names from many different countries, as found in PubChem. Other properties in this data set are derived from one or more of these codes, such as official names of pharmacological and chemical subgroups, and defined daily doses (DDD).

- **antivirals**

A 'data.frame' containing 102 antiviral agents with 9 columns. Like the **antibiotics** data set, it contains ATC codes (as used by the WHO (WHO Collaborating Centre

for Drug Statistics Methodology 2018)), and a CID code (Compound ID, as used by PubChem (Kim *et al.* 2019)), as well as the official name and defined daily dose (DDD) for each antiviral agent.

- **example\_isolates**

A 'data.frame' containing test results of 2,000 microbial isolates. The data set reflects real patient data and can be used to practice AMR analysis. It is structured in the typical format of laboratory information systems with one row per isolate and one column per tested antimicrobial agent (i.e. an antibiogram).

- **WHONET**

A 'data.frame' containing 500 observations and 53 columns, with the exact same structure as an export file from WHONET 2019 software (WHO Collaborating Centre for Surveillance of Antimicrobial Resistance 2019). Such files can be used with the **AMR** package, as this example data set demonstrates. The data itself was based on the **example\_isolates** data set.

## Computational details

The results in this paper were obtained using R 3.6.1 in RStudio 1.2.5019 (RStudio Team 2019) with the **AMR** package 0.9.0, running under macOS Catalina 10.15.1.

R itself and all packages used are available from the Comprehensive R Archive Network (CRAN) at <https://CRAN.R-project.org/>.

## Acknowledgments

The authors Matthijs S. Berends and Christian F. Luz contributed equally to this publication. For their contributions to the development of the **AMR** package, we would like to thank (in alphabetical order) dr. Judith M. Fonville, Erwin E.A. Hassing, Eric H.L.C.M. Hazenberg, Annick Lenglet, dr. Bart C. Meijer, dr. Sofia Ny and dr. Dennis Souverein.

The development of the **AMR** package was partly supported by the INTERREG V A (202085) funded project EurHealth-1Health (<http://www.eurhealth1health.eu>), part of a Dutch-German cross-border network supported by the European Commission, the Dutch Ministry of Health, Welfare and Sport, the Ministry of Economy, Innovation, Digitalisation and Energy of the German Federal State of North Rhine-Westphalia and the Ministry for National and European Affairs and Regional Development of Lower Saxony.

Furthermore, the **AMR** package was developed as part of a project funded by the European Commission Horizon 2020 Framework Marie Skłodowska-Curie Actions (grant agreement number: 713660-PRONKJEWAIL-H2020-MSCA-COFUND-2015).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## References

- Abat C, Fournier PE, Jimeno MT, Rolain JM, Raoult D (2018). “Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?” *European Journal of Clinical Microbiology & Infectious Diseases*, **37**(9), 1687–1697. ISSN 0934-9723. doi:10.1007/s10096-018-3300-0. URL <http://www.ncbi.nlm.nih.gov/pubmed/29956024><http://link.springer.com/10.1007/s10096-018-3300-0>.
- Berends MS, Luz CF, Friedrich AW, Sinha BNM, Albers CJ, Glasner C (2019). *AMR: Antimicrobial Resistance Analysis*. R package version 0.9.0, URL <https://CRAN.R-project.org/package=AMR>.
- Cavalier-Smith T (2002). “The neomuran origin of archaeobacteria, the negibacterial root of the universal tree and bacterial megaclassification.” *International journal of systematic and evolutionary microbiology*, **52**(Pt 1), 7–76. ISSN 1466-5026. doi:10.1099/00207713-52-1-7. URL <http://www.ncbi.nlm.nih.gov/pubmed/11837318>.
- CDC (2019). “AR Threats Report: Antibiotic Resistance Threats in the United States, 2019.” <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>.
- Clinical and Laboratory Standards Institute (2014). “M39-A4, Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data, 4th Edition.”
- Clinical and Laboratory Standards Institute (2019). “Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1, 2nd Edition.”
- Courvalin P (1992). “Interpretive reading of antimicrobial susceptibility tests. Molecular analysis and therapeutic interpretation of in vitro tests to improve antibiotic therapy.” *ASM American Society for Microbiology News*, **58**(7), 368–375.
- Courvalin P (1996). “Interpretive reading of in vitro antibiotic susceptibility tests (the antibiogramme).” *Clin. Microbiol. Infect.*, **2**, S26–S34. doi:10.1111/j.1469-0691.1996.tb00872.x.
- de Greeff SC, Mouton JW, Schoffelen AF, Verduin CM (2019). “NethMap 2019: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands / MARAN 2019: Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2018.”
- de Kraker MEA, Stewardson AJ, Harbarth S (2016). “Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?” *PLoS Med.*, **13**(11), e1002184. doi:10.1371/journal.pmed.1002184.
- EUCAST (2019). “EUCAST New definitions of S, I and R from 2019.” <http://www.eucast.org/newsiandr/>. Accessed: 2019-12-02.
- European Centre for Disease Prevention and Control (2010). “European Antimicrobial Resistance Surveillance Network (EARS-Net).” <https://ecdc.europa.eu/en/about-us/>

- [partnerships-and-networks/disease-and-laboratory-networks/ears-net](#). Accessed: 2019-4-9.
- European Centre for Disease Prevention and Control (2018). “Antimicrobial resistance (AMR) reporting protocol 2018. European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2017.”
- European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2016). “EUCAST Expert Rules, Intrinsic Resistance and Exceptional Phenotypes Tables. Version 3.1, 2016.” [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Expert\\_Rules/Expert\\_rules\\_intrinsic\\_exceptional\\_V3.1.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Expert_Rules/Expert_rules_intrinsic_exceptional_V3.1.pdf).
- Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE (2019). “PubChem 2019 update: improved access to chemical data.” *Nucleic Acids Res.*, **47**(D1), D1102–D1109. doi:10.1093/nar/gky1033.
- Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013). “EUCAST expert rules in antimicrobial susceptibility testing.” *Clin. Microbiol. Infect.*, **19**(2), 141–160. doi:0.1111/j.1469-0691.2011.03703.x.
- Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN, Holmes AH, Moore CE, Dolecek C, van Doorn HR, Shetty N, Lopez AD, Peacock SJ, Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) (2019). “Improving the estimation of the global burden of antimicrobial resistant infections.” *Lancet Infect. Dis.* doi:10.1016/S1473-3099(19)30276-2.
- Livermore DM, Winstanley TG, Shannon KP (2001). “Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes.” *J. Antimicrob. Chemother.*, **48 Suppl 1**, 87–102. doi:10.1093/jac/48.suppl\_1.87.
- Lowndes JSS, Best BD, Scarborough C, Afflerbach JC, Frazier MR, O’Hara CC, Jiang N, Halpern BS (2017). “Our path to better science in less time using open data science tools.” *Nat Ecol Evol*, **1**(6), 160. doi:10.1038/s41559-017-0160.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012). “Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.” *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, **18**(3), 268–81. ISSN 1469-0691. doi:10.1111/j.1469-0691.2011.03570.x. URL <http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x><http://www.ncbi.nlm.nih.gov/pubmed/21793988>.
- Müller J, Voss A, Köck R, Sinha B, Rossen JW, Kaase M, Mielke M, Daniels-Haardt I, Jurke A, Hendrix R, Kluytmans JA, Kluytmans-van den Bergh MF, Pulz M, Herrmann J, Kern WV, Wendt C, Friedrich AW (2015). “Cross-border comparison of the Dutch and German guidelines on multidrug-resistant Gram-negative microorganisms.” *Antimicrobial resistance and infection control*, **4**, 7. ISSN 2047-2994. doi:10.1186/

- s13756-015-0047-6. URL <http://www.ncbi.nlm.nih.gov/pubmed/25763183><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4355569>.
- O'Neill J (2014). "Antimicrobial resistance: tackling a crisis for the health and wealth of nations."
- Roskov Y, Ower G, Orrell T, Nicolson D, Bailly N, Kirk PM, Bourgoin T, DeWalt RE, Decock W, Nieukerken Ev, Zarucchi J, Penev L (2019). "Species 2000 & ITIS Catalogue of Life, 25th March 2019." *Digital resource at www.catalogueoflife.org/col. Species 2000: Naturalis*.
- RStudio Team (2019). *RStudio: Integrated Development Environment for R*. RStudio, Inc., Boston, MA. URL <http://www.rstudio.com/>.
- Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J, EPI-Net COMBACTE-MAGNET Group (2018). "Surveillance for control of antimicrobial resistance." *Lancet Infect. Dis.*, **18**(3), e99–e106. doi: [10.1016/S1473-3099\(17\)30485-1](https://doi.org/10.1016/S1473-3099(17)30485-1).
- The European Committee on Antimicrobial Susceptibility Testing (2019). "Breakpoint tables for interpretation of MICs and zone diameters, version 9.0, 2019." [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/).
- Werkgroep Infectiepreventie (WIP) (2011). "Bijzonder resistente micro-organismen (BRMO)."
- WHO Collaborating Center for Drug Statistics Methodology (2019). "ATC/DDD Index." [https://www.whocc.no/atc\\_ddd\\_index/](https://www.whocc.no/atc_ddd_index/). Accessed: 2019-4-9.
- WHO Collaborating Centre for Drug Statistics Methodology (2018). "Guidelines for ATC classification and DDD assignment."
- WHO Collaborating Centre for Surveillance of Antimicrobial Resistance (2019). "WHONET." <http://www.whonet.org/>. Accessed: 2019-7-16.
- Wickham H (2014). "Tidy Data." *Journal of Statistical Software*, **59**(10). ISSN 1548-7660. doi: [10.18637/jss.v059.i10](https://doi.org/10.18637/jss.v059.i10). URL <http://www.jstatsoft.org/v59/i10/>.
- Wickham H (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York. ISBN 978-3-319-24277-4. doi: [10.1007/978-3-319-24277-4](https://doi.org/10.1007/978-3-319-24277-4). URL <https://ggplot2.tidyverse.org>.
- Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H (2019a). "Welcome to the tidyverse." *Journal of Open Source Software*, **4**(43), 1686. doi: [10.21105/joss.01686](https://doi.org/10.21105/joss.01686).
- Wickham H, François R, Henry L, Müller K (2019b). *dplyr: A Grammar of Data Manipulation*. R package version 0.8.3, URL <https://CRAN.R-project.org/package=dplyr>.
- Winstanley T, Courvalin P (2011). "Expert systems in clinical microbiology." *Clin. Microbiol. Rev.*, **24**(3), 515–556. doi: [10.1128/CMR.00061-10](https://doi.org/10.1128/CMR.00061-10).



World Health Organization (2014). “Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.”

World Health Organization (2018a). “Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2017-2018.”

World Health Organization (2018b). “Global tuberculosis report 2018.”

### **Affiliation:**

Matthijs S. Berends  
 Certe Medical Diagnostics and Advice  
 Van Swietenlaan 2  
 9728 NZ Groningen, The Netherlands  
*and*  
 University of Groningen  
 University Medical Center Groningen  
 Department of Medical Microbiology and Infection Prevention  
 Hanzeplein 1  
 9713 GZ Groningen, The Netherlands  
 E-mail: [m.berends@certe.nl](mailto:m.berends@certe.nl), [m.s.berends@umcg.nl](mailto:m.s.berends@umcg.nl)

Christian F. Luz  
 University of Groningen  
 University Medical Center Groningen  
 Department of Medical Microbiology and Infection Prevention  
 Hanzeplein 1  
 9713 GZ Groningen, The Netherlands  
 Alexander W. Friedrich  
 University of Groningen  
 University Medical Center Groningen  
 Department of Medical Microbiology and Infection Prevention  
 Hanzeplein 1  
 9713 GZ Groningen, The Netherlands

Bhanu N.M. Sinha  
 University of Groningen  
 University Medical Center Groningen  
 Department of Medical Microbiology and Infection Prevention  
 Hanzeplein 1  
 9713 GZ Groningen, The Netherlands

Casper J. Albers  
 University of Groningen  
 Heymans Institute for Psychological Research  
 Grote Kruisstraat 2/1  
 9712 TS Groningen, The Netherlands

*Berends MS, Luz CF, Friedrich AW, Sinha BNM, Albers CJ, Glasner C* 23

Corinna Glasner  
University of Groningen  
University Medical Center Groningen  
Department of Medical Microbiology and Infection Prevention  
Hanzeplein 1  
9713 GZ Groningen, The Netherlands